{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:57:04Z","timestamp":1784998624549,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013015","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000}}],"reference-count":118,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013015.pub2","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T22:56:00Z","timestamp":1571180160000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure"],"prefix":"10.1002","volume":"2019","author":[{"given":"Claire","family":"Sweeney","sequence":"first","affiliation":[{"name":"The Heartbeat Trust; Dublin Ireland"},{"name":"Trinity College Dublin; School of Pharmacy and Pharmaceutical Sciences; Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Ryan","sequence":"additional","affiliation":[{"name":"The Heartbeat Trust; Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ledwidge","sequence":"additional","affiliation":[{"name":"The Heartbeat Trust; Dublin Ireland"},{"name":"University College Dublin; School of Medicine and Medical Science; Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristin","family":"Ryan","sequence":"additional","affiliation":[{"name":"Trinity College Dublin; School of Pharmacy and Pharmaceutical Sciences; Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"McDonald","sequence":"additional","affiliation":[{"name":"The Heartbeat Trust; Dublin Ireland"},{"name":"University College Dublin; School of Medicine and Medical Science; Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Watson","sequence":"additional","affiliation":[{"name":"Queen's University Belfast; Wellcome-Wolfson Institute for Experimental Medicine; Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebabonye B","family":"Pharithi","sequence":"additional","affiliation":[{"name":"The Heartbeat Trust; Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Irish College of General Practitioners; Lincoln Place Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"10.1002\/14651858.CD013015.pub2-BIB0002|cit1","unstructured":"NCT00562952. Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC) clinicaltrials.gov\/ct2\/show\/NCT00562952"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0001|cit2","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","article-title":"PONTIAC (NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial","volume":"62 (16)","author":"Huelsmann","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0006|cit3","unstructured":"NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP-HF) clinicaltrials.gov\/ct2\/show\/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&rank=1"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0003|cit4","unstructured":"Ledwidge M McDonald K St Vincent's Screening TO Prevent Heart Failure (STOP-HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at-risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18\/09\/2018) Data on file"},{"issue":"7","key":"10.1002\/14651858.CD013015.pub2-BIB0004|cit5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ejhf.286","article-title":"Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent's Screening TO Prevent Heart Failure) study","volume":"17","author":"Ledwidge","year":"2015","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0005|cit6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.2013.7588","article-title":"Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial","volume":"310 (1)","author":"Ledwige","year":"2013","journal-title":"Journal of the American Medical Association"},{"issue":"11","key":"10.1002\/14651858.CD013015.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.663","article-title":"Biomarker-based risk prediction in the community","volume":"18","author":"AbouEzzeddine","year":"2016","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0008|cit8","unstructured":"ACTRN12618002005235 Biomarker-guided risk management for secondary prevention following acute coronary syndromes: a feasibility study http:\/\/apps.who.int\/trialsearch\/ACTRN12618002005235"},{"issue":"7","key":"10.1002\/14651858.CD013015.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2009.08.078","article-title":"N-terminal pro-B-type natriuretic peptide-guided intensive patient management in addition to multidisciplinary care in chronic heart failure: a 3-arm, prospective, randomized pilot study","volume":"55","author":"Berger","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD013015.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cardfail.2008.12.002","article-title":"The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study","volume":"15","author":"Betti","year":"2009","journal-title":"Journal of Cardiac Failure"},{"issue":"25","key":"10.1002\/14651858.CD013015.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.jacc.2010.07.030","article-title":"Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study","volume":"56","author":"Eurlings","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013015.pub2-BIB0012|cit12","first-page":"A15360","article-title":"Biomarker-guided heart failure therapy results in significant reverse left ventricular remodeling among patients achieving NT-proBNP goal: insights from the GUIDE-IT triaL","volume":"136","author":"Daubert","year":"2017","journal-title":"Circulation: Heart Failure"},{"issue":"8","key":"10.1002\/14651858.CD013015.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.2017.10565","article-title":"Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"318","author":"Felker","year":"2017","journal-title":"Journal of the American Medical Association"},{"issue":"18","key":"10.1002\/14651858.CD013015.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.jacc.2011.03.072","article-title":"Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction","volume":"58","author":"Januzzi","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"issue":"16","key":"10.1002\/14651858.CD013015.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2006.10.081","article-title":"Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study","volume":"49","author":"Jourdain","year":"2007","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD013015.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jacc.2009.02.095","article-title":"N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial","volume":"55","author":"Lainchbury","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0017|cit17","unstructured":"NCT00604006 SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study) https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00604006"},{"issue":"12","key":"10.1002\/14651858.CD013015.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/eurjhf\/hfq169","article-title":"Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure - SIGNAL-HF (Swedish Intervention study - Guidelines and NT-proBNP AnaLysis in Heart Failure)","volume":"12","author":"Persson","year":"2010","journal-title":"European Journal of Heart Failure"},{"issue":"18","key":"10.1002\/14651858.CD013015.pub2-BIB0019|cit19","first-page":"528","article-title":"STARBRITE: a randomized pilot trial of BNP-guided therapy in patients with advanced heart failure","volume":"114","author":"Shah","year":"2006","journal-title":"Circulation: Heart Failure"},{"issue":"5","key":"10.1002\/14651858.CD013015.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cardfail.2017.02.001","article-title":"N-terminal pro-B-type natriuretic peptide-guided therapy in chronic heart failure reduces repeated hospitalizations - results from TIME-CHF","volume":"23","author":"Davarzan","year":"2017","journal-title":"Journal of Cardiac Failure"},{"issue":"Suppl 21","key":"10.1002\/14651858.CD013015.pub2-BIB0021|cit21","first-page":"A17200","article-title":"Evolution of left ventricular ejection fraction and left ventricular volumes in elderly heart failure patients under modern heart failure therapy: influence of BNP-guided therapy","volume":"126","author":"Kauffman","year":"2012","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD013015.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/jama.2009.2","article-title":"BNP-guided vs symptom-guided heart failure therapy: the trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial","volume":"301","author":"Pfisterer","year":"2009","journal-title":"Journal of the American Medical Association"},{"issue":"1","key":"10.1002\/14651858.CD013015.pub2-BIB0023|cit23","first-page":"131","article-title":"Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF","volume":"7","author":"Sanders-van Wijk","year":"2013","journal-title":"Circulation: Heart Failure"},{"issue":"9210","key":"10.1002\/14651858.CD013015.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(00)02060-2","article-title":"Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations","volume":"355","author":"Troughton","year":"2000","journal-title":"The Lancet"},{"issue":"16","key":"10.1002\/14651858.CD013015.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.2174\/092986712800492977","article-title":"Biomarkers as a guide of medical treatment in cardiovascular diseases","volume":"19","author":"Vavuranakis","year":"2012","journal-title":"Current Medicinal Chemistry"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0026|cit26","first-page":"6","article-title":"NT proBNP - an important decision factor in preventing heart failure","volume":"2","author":"Dimitriu","year":"2015","journal-title":"European Journal of Clinical Investigation"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0027|cit27","first-page":"420","article-title":"Preventing heart failure using medical intervention guided by NTproBNP","volume":"17","author":"Dimitriu","year":"2015","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0028|cit28","unstructured":"Dimitriu I Raileanu M Andrei C Sinescu C NTproBNP - an important decision factor in preventing heart failure Proceedings of the 49th Annual Society Meeting of the European Society for Clinical Investigation 2015 147 51"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1097\/01.hjh.0000468836.50213.4f","article-title":"Preventing heart failure using medical intervention guided by NTproBNP","volume":"33","author":"Dimitriu","year":"2015","journal-title":"Journal of Hypertension"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013015.pub2-BIB0030|cit30","first-page":"100","article-title":"Role of NT proBNP in preventing left ventricular dysfunction in diabetic patients","volume":"47","author":"Dimitriu","year":"2017","journal-title":"European Journal of Clinical Investigation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013015.pub2-BIB0031|cit31","first-page":"249","article-title":"Role of NT proBNP in preventing left ventricular dysfunction in hypertensive patients","volume":"18","author":"Dimitriu","year":"2016","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0032|cit32","first-page":"15","article-title":"NTproBNP in patients with hypertension to prevent heart failure","volume":"1","author":"Dimitriu","year":"2016","journal-title":"European Journal of Clinical Investigation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013015.pub2-BIB0033|cit33","first-page":"408","article-title":"NT pro BNP - a decision factor in preventing heart failure in diabetic patients","volume":"9","author":"Dimitriu","year":"2017","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0034|cit34","first-page":"228","article-title":"Preventing heart failure using medical intervention guided by NTproBNP","volume":"1","author":"Dimitriu I. Preventing heart failure using medical intervention guided by NTproBNP","year":"2015","journal-title":"Journal of Economic Computation and Economic Cybernetics Studies and Research"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0035|cit35","unstructured":"NCT02817360. NT-proBNP selected prevention of cardiac events in diabetic patients clinicaltrials.gov\/ct2\/show\/NCT02817360?term=PONTIAC&rank=2"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"553-64","DOI":"10.1007\/s10741-014-9451-x","article-title":"B-type natriuretic peptide-guided therapy: a systematic review","volume":"19","author":"Balion","year":"2014","journal-title":"Heart Failure Review"},{"issue":"23","key":"10.1002\/14651858.CD013015.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJM199806043382302","article-title":"Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults","volume":"338","author":"Berenson","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"2168-74","DOI":"10.1161\/01.CIR.0000144310.04433.BE","article-title":"N-terminal pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients","volume":"110","author":"Bettencourt","year":"2004","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD013015.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cardfail.2008.12.002","article-title":"The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study","volume":"15","author":"Betti","year":"2009","journal-title":"Journal of Cardiac Failure"},{"issue":"2","key":"10.1002\/14651858.CD013015.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/CIRCULATIONAHA.106.621417","article-title":"Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications","volume":"1142","author":"Chiuve","year":"2006","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD013015.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jacc.2009.07.069","article-title":"Dynamic cardiovascular risk assessment in elderly people: the role of repeated N-terminal pro-B-type natriuretic peptide testing","volume":"55","author":"Christenson","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD013015.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1373\/clinchem.2003.024760","article-title":"Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review","volume":"50","author":"Clerico","year":"2004","journal-title":"Clinical Chemistry"},{"issue":"5","key":"10.1002\/14651858.CD013015.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1373\/clinchem.2006.075713","article-title":"Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the n-terminal part of the pro-peptide of BNP immunoassays in chronic and acute heart failure: a systematic review","volume":"53","author":"Clerico","year":"2007","journal-title":"Clinical Chemistry"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0044|cit44","first-page":"122-34","article-title":"B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis","volume":"15(2)","author":"Vecchis","year":"2014","journal-title":"Journal of Cardiovascular Medicine"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0045|cit45","unstructured":"Deeks JJ Higgins JP Altman DG (editors) on behalf of the Cochrane Statistical Methods Group Chapter 9. Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD013015.pub2-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001561.pub3","article-title":"Multiple risk factor interventions for primary prevention of coronary heart disease","author":"Ebrahim","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"25","key":"10.1002\/14651858.CD013015.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.jacc.2010.07.030","article-title":"Management of chronic heart failure guided by individual n-terminal pro-b-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study","volume":"56","author":"Eurlings","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD013015.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cjca.2017.08.022","article-title":"2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure","volume":"33","author":"Ezekowitz","year":"2017","journal-title":"Canadian Journal of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD013015.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jacc.2007.09.065","article-title":"Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation","volume":"51","author":"Fang","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0050|cit50","first-page":"67","article-title":"Biological variation: from principles to practice","volume-title":"Biological Variation: From Principles to Practice","author":"Fraser","year":"2006"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0051|cit51","first-page":"1735-43","article-title":"N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure","volume":"24","author":"Gardner","year":"2003","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD013015.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.amjcard.2010.11.003","article-title":"Placental growth factor and b-type natriuretic peptide as independent predictors of risk from a multi-biomarker panel in suspected acute coronary syndrome (Acute Risk and Related Outcomes assessed With cardiac biomarkers [ARROW]) study","volume":"107","author":"Glaser","year":"2011","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD013015.pub2-BIB0053|cit53","first-page":"228","article-title":"Heart disease and stroke statistics. 2014 update: a report from the American Heart Association","volume":"129","author":"Go","year":"2014","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0054|cit54","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"issue":"3","key":"10.1002\/14651858.CD013015.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/hrt.2003.026021","article-title":"Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population","volume":"90","author":"Groenning","year":"2004","journal-title":"Heart"},{"issue":"6","key":"10.1002\/14651858.CD013015.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jacc.2003.10.043","article-title":"Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction","volume":"43","author":"Heidenreich","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0057|cit57","unstructured":"Health Economics Research Centre CVD costs in Europe: the economic burden of cardiovascular disease in the enlarged European Union www.herc.ox.ac.uk\/research\/disease-cost-studies-1\/studies-14\/cvd-costs-in-europe-the-economic-burden-of-cardiovascular-disease-in-the-enlarged-european-union-1"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0058|cit58","unstructured":"Higgins JP Altman DG Sterne JAC (editors) Chapter 8. Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"13","key":"10.1002\/14651858.CD013015.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1161\/CIRCULATIONAHA.111.038729","article-title":"Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy","volume":"125","author":"Hijazi","year":"2012","journal-title":"Circulation"},{"issue":"22","key":"10.1002\/14651858.CD013015.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.jacc.2012.11.082","article-title":"N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation)","volume":"61","author":"Hijazi","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"20","key":"10.1002\/14651858.CD013015.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/eurheartj\/ehw054","article-title":"The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation","volume":"37","author":"Hijazi","year":"2016","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0062|cit62","first-page":"353","article-title":"Natriuretic peptide should be used as a routine tool for evaluation of patients with atrial fibrillation","volume":"105","author":"Hijazi","year":"2019","journal-title":"Heart"},{"issue":"2","key":"10.1002\/14651858.CD013015.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00392-013-0628-4","article-title":"B-type natriuretic peptide: distribution in the general population and the association with major cardiovascular and coronary events - the Heinz Nixdorf Recall Study","volume":"103","author":"Kara","year":"2014","journal-title":"Clinical Research in Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD013015.pub2-BIB0064|cit64","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008966","article-title":"B-type natriuretic peptide-guided treatment for heart failure","author":"Kearley","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD013015.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jacc.2007.10.034","article-title":"The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention","volume":"51","author":"Kip","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD013015.pub2-BIB0066|cit66","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009009.pub2","article-title":"General health checks in adults for reducing morbidity and mortality from disease","author":"Krogsb\u00f8ll","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013015.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/01.CIR.92.4.720","article-title":"Subclinical disease as an independent risk factor for cardiovascular disease","volume":"92","author":"Kuller","year":"1995","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD013015.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ejhf.286","article-title":"Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent's Screening TO Prevent Heart Failure) study","volume":"17","author":"Ledwidge","year":"2015","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0069|cit69","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6. Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0070|cit70","first-page":"852-60","article-title":"B-type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials","volume":"22(1)","author":"Li","year":"2013","journal-title":"Heart, Lung and Circulation"},{"issue":"2","key":"10.1002\/14651858.CD013015.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD013015.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1161\/CIRCULATIONAHA.105.548206","article-title":"Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age","volume":"133","author":"Lloyd-Jones","year":"2006","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD013015.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0002-8703(98)70041-9","article-title":"Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction","volume":"135","author":"Maeda","year":"1998","journal-title":"American Heart Journal"},{"issue":"9095","key":"10.1002\/14651858.CD013015.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(97)03034-1","article-title":"Biochemical detection of left-ventricular systolic dysfunction","volume":"351","author":"McDonagh","year":"1998","journal-title":"The Lancet"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0075|cit75","first-page":"ii12","article-title":"Screening for left ventricular dysfunction: a step too far?","volume":"88(Suppl 2)","author":"McDonagh","year":"2002","journal-title":"Heart"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/eurjhf\/hft001","article-title":"N-terminal b-type natriuretic peptide and the association with left ventricular diastolic function in a population at high risk of incident heart failure: results of the SCReening Evaluation of the Evolution of New-Heart Failure Study (SCREEN-HF)","volume":"14","author":"McGrady","year":"2013","journal-title":"European Journal of Heart Failure"},{"issue":"26","key":"10.1002\/14651858.CD013015.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJM197112232852601","article-title":"The natural history of congestive heart failure: the Framingham Study","volume":"285","author":"McKee","year":"1971","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD013015.pub2-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008966.pub2","article-title":"B-type natriuretic peptide-guided treatment for heart failure","author":"McLellan","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD013015.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/ejhf.636","article-title":"Biomarkers to identify and prevent new-onset heart failure in the community","volume":"18","author":"Meijers","year":"2016","journal-title":"European Journal of Heart Failure"},{"issue":"4","key":"10.1002\/14651858.CD013015.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.114.000907","article-title":"B-type natriuretic peptides for the prediction of cardiovascular events in patients with stable coronary heart disease: the heart and soul study","volume":"3","author":"Mishra","year":"2014","journal-title":"Journal of the American Heart Association"},{"issue":"1","key":"10.1002\/14651858.CD013015.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cjca.2014.10.022","article-title":"The 2014 Canadian Cardiovascular Society heart failure management guidelines focus update: anemia, biomarkers, and recent therapeutic trial implications","volume":"31","author":"Moe","year":"2015","journal-title":"Canadian Journal of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD013015.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2012.04.049","article-title":"Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease","volume":"60","author":"Nadir","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD013015.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jacc.2004.12.058","article-title":"Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptide","volume":"45","author":"Ng","year":"2005","journal-title":"Journal of the American College of Cardiology"},{"issue":"42","key":"10.1002\/14651858.CD013015.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1093\/eurheartj\/ehu299","article-title":"Cardiovascular disease in Europe 2014: epidemiological update","volume":"35","author":"Nichols","year":"2014","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD013015.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0735-1097(02)02625-6","article-title":"Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population","volume":"41","author":"Nielsen","year":"2003","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cardfail.2006.09.003","article-title":"The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients","volume":"13","author":"O'Hanlon","year":"2007","journal-title":"Journal of Cardiac Failure"},{"issue":"11","key":"10.1002\/14651858.CD013015.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/eurheartj\/ehl448","article-title":"N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population","volume":"28","author":"Olsen","year":"2007","journal-title":"European Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD013015.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1536\/ihj.53.176","article-title":"Plasma b-type natriuretic peptide is useful for cardiovascular risk assessment in community-based diabetes subjects: comparison with albuminuria","volume":"53","author":"Onodera","year":"2012","journal-title":"International Heart Journal"},{"issue":"24","key":"10.1002\/14651858.CD013015.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1136\/heartjnl-2013-304724","article-title":"N-terminal pro-B-type natriuretic peptide as a predictor of incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis: the effects of age, sex and ethnicity","volume":"99","author":"Patton","year":"2013","journal-title":"Heart"},{"issue":"11","key":"10.1002\/14651858.CD013015.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"e49259","DOI":"10.1371\/journal.pone.0049259","article-title":"Modest elevation in BNP in asymptomatic hypertensive patients reflects sub-clinical cardiac remodeling, inflammation and extracellular matrix changes","volume":"7","author":"Phelan","year":"2012","journal-title":"PLoS One"},{"issue":"29","key":"10.1002\/14651858.CD013015.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice","volume":"37","author":"Piepoli","year":"2016","journal-title":"European Heart Journal"},{"issue":"27","key":"10.1002\/14651858.CD013015.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/archinternmed.2010.35","article-title":"B-type natriuretic peptide-guided heart failure therapy: a meta-analysis","volume":"170(6)","author":"Porapakkham","year":"2010","journal-title":"Archives of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD013015.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD013015.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/heart.89.7.745","article-title":"The influence of age, sex and other variables on the plasma level of n-terminal pro brain natriuretic peptide in a large sample of the general population","volume":"89","author":"Raymond","year":"2003","journal-title":"Heart"},{"issue":"5","key":"10.1002\/14651858.CD013015.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0735-1097(02)02059-4","article-title":"Plasma brain natriuretic peptide concentration: impact of age and gender","volume":"40","author":"Redfield","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0097|cit97","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0098|cit98","unstructured":"Ryan R Heterogeneity and subgroup analyses in Cochrane Consumers and Communication Group reviews: planning the analysis at protocol stage cccrg.cochrane.org"},{"issue":"10","key":"10.1002\/14651858.CD013015.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.jacc.2004.07.057","article-title":"Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia","volume":"44","author":"Sabatine","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD013015.pub2-BIB0100|cit100","first-page":"2326","article-title":"Epidemiology of cardiovascular disease in the 21st century: updated numbers and updated facts","volume":"1","author":"Santulli","year":"2013","journal-title":"Journal of Cardiovascular Disease"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0101|cit101","first-page":"e96706","article-title":"Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials","volume":"8(3)","author":"Savarese","year":"2013","journal-title":"PLOS One"},{"issue":"2","key":"10.1002\/14651858.CD013015.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1161\/CIRCULATIONAHA.109.882241","article-title":"Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community","volume":"121","author":"Schnabel","year":"2010","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD013015.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/eurheartj\/ehq468","article-title":"Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 Trial","volume":"32","author":"Scirica","year":"2011","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"f1342","DOI":"10.1136\/bmj.f1342","article-title":"Selection bias versus allocation bias","volume":"346","author":"Sedgwick","year":"2013","journal-title":"British Medical Journal"},{"issue":"9","key":"10.1002\/14651858.CD013015.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.amjcard.2003.07.010","article-title":"Brain natriuretic peptide is elevated in outpatients with atrial fibrillation","volume":"92","author":"Silvet","year":"2003","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"2256-326","DOI":"10.1007\/s00125-006-0359-4","article-title":"Plasma n-terminal pro-b-type natriuretic peptide and mortality in type 2 diabetes","volume":"49","author":"Tarnow","year":"2006","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ijcard.2015.07.080","article-title":"Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: the LIPID biomarker study","volume":"201","author":"Tonkin","year":"2015","journal-title":"International Journal of Cardiology"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/eurheartj\/ehu090","article-title":"Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalisation: an individual patient meta-analysis","volume":"35","author":"Troughton","year":"2014","journal-title":"European Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD013015.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0002-9149(02)02464-5","article-title":"Impact of age and sex on plasma natriuretic peptide levels in healthy adults","volume":"90","author":"Wang","year":"2002","journal-title":"American Journal of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD013015.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMoa031994","article-title":"Plasma natriuretic peptide levels and the risk of cardiovascular events and death","volume":"350","author":"Wang","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"25","key":"10.1002\/14651858.CD013015.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1056\/NEJMoa055373","article-title":"Multiple biomarkers for the prediction of first major cardiovascular events and death","volume":"355","author":"Wang","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD013015.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/eurheartj\/ehs239","article-title":"N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS","volume":"34","author":"Welsh","year":"2012","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0113|cit113","unstructured":"World Health Organization Cardiovascular diseases (CVDs). Fact Sheet Number 317, 2013 http:\/\/www.who.int\/mediacentre\/factsheets\/fs317\/en\/index.html (accessed 8 January 2019)"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0114|cit114","unstructured":"World Health Organization Cardiovascular diseases fact sheet www.who.int\/mediacentre\/factsheets\/fs317\/en\/"},{"issue":"16","key":"10.1002\/14651858.CD013015.pub2-BIB0115|cit115","first-page":"240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/CIR.0000000000000509","article-title":"ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD013015.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1161\/01.CIR.87.2.464","article-title":"Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure","volume":"87","author":"Yoshimura","year":"1993","journal-title":"Circulation"},{"issue":"20","key":"10.1002\/14651858.CD013015.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1056\/NEJMoa0707064","article-title":"Use of multiple biomarkers to improve the prediction of death from cardiovascular causes","volume":"358","author":"Zethelius","year":"2008","journal-title":"New England Journal of Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD013015.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T16:01:23Z","timestamp":1633708883000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013015.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Heart Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":118,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013015.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]}}}